Virginia STEM News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Virginia STEM News.

Press releases published on March 2, 2026

Mar. 2, 2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Mar. 2, 2026

Altimmune to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Mar. 2, 2026

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

Indeterminate GlobeNewswire

Mar. 2, 2026

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Indeterminate GlobeNewswire

Mar. 2, 2026

Wrap and WOFT Establish Drone Test & Non-Lethal Response Training Site in Florida

Indeterminate GlobeNewswire

Mar. 2, 2026

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Indeterminate GlobeNewswire

Mar. 2, 2026

Telkomsel Expands Capsyl Cloud Deployment with Synchronoss

Indeterminate GlobeNewswire

Mar. 2, 2026

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

Indeterminate GlobeNewswire

Mar. 2, 2026

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Indeterminate GlobeNewswire

Mar. 2, 2026

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Indeterminate GlobeNewswire

Mar. 2, 2026

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

Indeterminate GlobeNewswire

Mar. 2, 2026

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Indeterminate GlobeNewswire

Mar. 2, 2026

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Indeterminate GlobeNewswire

Mar. 2, 2026

Beyond Binary: Qubic’s Neuraxon 2.0 Introduces a Trinary Architecture for Continuous, Adaptive AI Systems

Indeterminate GlobeNewswire

Mar. 2, 2026

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

Indeterminate GlobeNewswire

Mar. 2, 2026

YAROOMS Introduces Yarvis: Not an App. A Colleague.

Indeterminate GlobeNewswire

Mar. 2, 2026

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Indeterminate GlobeNewswire

Mar. 2, 2026

NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

Indeterminate GlobeNewswire

Mar. 2, 2026

MapLight Therapeutics to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Mar. 2, 2026

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

Indeterminate GlobeNewswire